Bavarian Nordic A/S (0DPB.IL)
| Previous close | 151.07 |
| Open | 151.20 |
| Bid | 147.50 x N/A |
| Ask | 155.05 x N/A |
| Day's range | 150.95 - 151.95 |
| 52-week range | 125.55 - 221.90 |
| Volume | |
| Avg. volume | 148,723 |
| Market cap | 14.192B |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | 10.73 |
| EPS (TTM) | 14.09 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transactions concern the vesting of restricted stock units (RSUs) awarded to members of the Board of Directors of Bavarian Nordic A/S as part of their remuneration for 2021, and in accordance with the decision by the
GlobeNewswireResolutions of the Annual General Meeting 2024 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2024 was also adopted.The Remuneration Report for 2023 was approved.The Board of Directors and the Board of Management were discharged from liability.Luc Debryune, Anders Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter and Johan van Hoo
- Globe Newswire
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers. Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at ris
